Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA Voices

FDA Voices Home
          News & Events
          FDA Newsroom
          FDA Voices
          Realizing the Promise of Real-World EvidenceFDA Voices Realizing the Promise of Real-World Evidence
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              Catching Up with Califf Main Image includes photo of Dr. Califf*By: Robert M. Califf, M.D., Commissioner of Food and Drugs*

What we now call real-world data (RWD) have been used for years in medical product development to inform study design and endpoint selection, identify potential participants and trial sites, and assess safety in the post-marketing setting.

Related, real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD. I’d like to catch up with you today on some of the challenges and advancements in RWD and RWE.

Understanding RWD, RWE and Challenges in the Ecosystem

It’s important to understand that RWD relate to patient health status and/or the delivery of health care routinely collected from a variety of sources. Examples of RWD include data derived from electronic health records, medical claims data, data from product or disease registries, and data gathered from other sources (such as digital health technologies) that can inform on health status. The key distinction is that RWD are not collected in a special research clinic or setting.

In addition to appropriate analysis, the study design is an essential part of producing RWE; and RWE can be generated by various types of study designs. These include non-interventional studies as well as interventional studies such as randomized trials with outcomes collected using RWD sources—so-called point-of-care trials—and externally controlled trials with control arms derived from RWD sources.

There is more recent interest in using RWE for regulatory decision-making in the pre-market setting, including to support a determination regarding a medical product’s effectiveness and inform benefit-risk analysis of devices for new intended uses. Realizing the full potential of RWE in regulatory decision-making presents several challenges, and work is underway at the FDA to better understand this area.

One challenge is finding fit-for-purpose RWD. Data from routine-care settings are focused on patients at the bedside or in the clinic, requiring consideration of the data’s reliability and relevance to address regulatory questions. For example, information on clinical measures of disease severity can be lacking in healthcare insurance claims, and we need better ways of examining unstructured data in electronic health records. Another category of challenges involves safeguarding patient privacy while having suitable mechanisms for data access and inspection by regulatory agencies. These challenges will require continued collaboration among a range of stakeholders including regulators, industry, academia and the clinical research community.

In this rapidly evolving world with a plethora of digital data, the FDA intends to help develop the best methods for RWD and RWE in the domains of data quality, study design and analysis.

FDA Guidance on Real-World Evidence and Data

The FDA has published a series of guidances to help advance real world evidence and recently published three additional guidances in this series:

Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices, which updates and clarifies how the FDA evaluates RWD to determine if it is sufficient to be used in regulatory decision making for medical devices and provides expanded recommendations for sponsors collecting RWD.
	Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products, which provides considerations for sponsors proposing to design a registry or to use an existing registry to support regulatory decision-making about a drug’s effectiveness or safety.
	Data Standards for Drug and Biological Product Submissions Containing Real-World Data, which addresses considerations for the use of data standards currently supported by the FDA in applicable drug submissions containing study data derived from RWD sources.Supporting a robust data infrastructure, developing new methods and analytical tools, and integrating RWE with traditional clinical trial evidence will require collaboration across the clinical care, research and technology sectors, in addition to direct involvement of patients. To help in this context, the FDA is supporting research (or “demonstration”) projects that seek to improve the quality of RWD and RWE. Strengthening systems for generating and gathering new and better data and analyzing those data to provide reliable evidence to inform and improve the many decisions we make as consumers, patients, families, clinicians and regulators, is key.

The FDA is already capable of reviewing submissions that include or rely entirely on RWD. Enabling advanced data analytics, including RWD, is also incorporated in the FDA’s Information Technology Strategy for FY 2024-2027. Ongoing agency initiatives will continue to promote awareness of, and consistency in, reviewing submissions with RWD.

Stay tuned in 2024 for an emphasis across our U.S. Health and Human Services agencies on RWE, including point of care prospective clinical trials, in the post-market and health policy arenas.

Catch up with you next time.

                                                                                  Content current as of:
      12/21/2023
              
              
Regulated Product(s)
		 Biologics
			  			     			  			     Drugs
			     			  			     Medical DevicesFDA Voices
 FDA Voices Email
                        Subscribe to receive FDA Voices email notifications.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop